Xponance Inc. Decreases Stake in Masimo Co. (NASDAQ:MASI)

Xponance Inc. reduced its holdings in Masimo Co. (NASDAQ:MASI) by 2.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,635 shares of the medical equipment provider’s stock after selling 256 shares during the quarter. Xponance Inc.’s holdings in Masimo were worth $1,129,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in MASI. Massachusetts Financial Services Co. MA bought a new stake in shares of Masimo in the 3rd quarter worth approximately $132,699,000. Eminence Capital LP bought a new stake in shares of Masimo in the 3rd quarter worth approximately $90,859,000. Hawk Ridge Capital Management LP grew its position in shares of Masimo by 124.4% in the 3rd quarter. Hawk Ridge Capital Management LP now owns 567,765 shares of the medical equipment provider’s stock worth $49,782,000 after buying an additional 314,763 shares during the last quarter. Hudson Bay Capital Management LP bought a new stake in shares of Masimo in the 3rd quarter worth approximately $12,497,000. Finally, Sei Investments Co. grew its position in shares of Masimo by 224.5% in the 3rd quarter. Sei Investments Co. now owns 183,940 shares of the medical equipment provider’s stock worth $16,128,000 after buying an additional 127,249 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors.

Masimo Trading Down 0.8 %

Masimo stock opened at $135.92 on Thursday. The company has a current ratio of 2.18, a quick ratio of 1.22 and a debt-to-equity ratio of 0.64. The business’s fifty day simple moving average is $135.72 and its two-hundred day simple moving average is $115.82. Masimo Co. has a 12 month low of $75.22 and a 12 month high of $195.82. The company has a market capitalization of $7.19 billion, a price-to-earnings ratio of 90.01 and a beta of 0.97.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, February 27th. The medical equipment provider reported $1.25 EPS for the quarter, topping the consensus estimate of $0.82 by $0.43. Masimo had a return on equity of 13.77% and a net margin of 3.98%. The business had revenue of $548.90 million for the quarter, compared to the consensus estimate of $545.69 million. During the same period in the previous year, the company posted $1.32 earnings per share. The company’s revenue for the quarter was down 11.0% compared to the same quarter last year. As a group, equities analysts predict that Masimo Co. will post 3.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on MASI. Wells Fargo & Company upgraded Masimo from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $117.00 to $160.00 in a research report on Monday, March 25th. BTIG Research lifted their price target on Masimo from $145.00 to $166.00 and gave the company a “buy” rating in a research report on Monday, March 25th. Piper Sandler lifted their price target on Masimo from $70.00 to $117.00 and gave the company a “neutral” rating in a research report on Monday, February 26th. Stifel Nicolaus upgraded Masimo from a “hold” rating to a “buy” rating and lifted their price target for the company from $148.00 to $170.00 in a research report on Monday, April 15th. Finally, Needham & Company LLC lowered Masimo from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $137.43.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.